Zydus Lifesciences growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+16.8%+16.3%
EBITDA+20.1%+30.0%
Net Income+9.7%+34.8%
EPS (adj.)+3,334.5%+37.0%
Total Assets+40.9%+26.7%
Total Equity+12.2%+14.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ZYDUSLIFE₹1,175.50

Zydus Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYCIPLATORNTPHARMDIVISLABMAXHEALTHAPOLLOHOSPAUROPHARMAMcap ₹1.18L Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+16.8+16.3
EBITDA+20.1+30.0
Net Income+9.7+34.8
EPS (adj.)+3334.5+37.0
Total Assets+40.9+26.7
Total Equity+12.2+14.5
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.